SCHEMBL6353567

SCHEMBL6353567

Cc1ccc(Nc2cc(N(C)C)nc(N3CCN(c4ccccn4)CC3)n2)c(NC(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 2/20 0.43
GALR1 P47211 1/20 0.43
ALDH1A1 P00352 8/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 6/20 0.41
KDM4E B2RXH2 6/20 0.41
LMNA P02545 4/20 0.41
HSD17B10 Q99714 3/20 0.41
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
PHGDH O43175 1/20 0.39
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 1/20 0.37
MCOLN3 Q8TDD5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242654 0.88 GALR2 (0.53) GALR2GALR1ALDH1A1MEN1KMT2A
SCHEMBL3236186 0.86 ALDH1A1 (0.52) GALR2GALR1ALDH1A1MEN1KMT2A
SCHEMBL3244112 0.86 ALDH1A1 (0.48) GALR2GALR1ALDH1A1MEN1KMT2A
SCHEMBL6350943 0.85 GALR2 (0.42) GALR2GALR1ALDH1A1MAPTKDM4E
SCHEMBL6353796 0.83 ALDH1A1 (0.42) GALR2GALR1ALDH1A1MEN1KMT2A
SCHEMBL8254119 0.83 KDM4E (0.48) GALR2GALR1ALDH1A1MAPTKDM4E
SCHEMBL3244443 0.81 PHGDH (0.47) GALR2GALR1ALDH1A1MAPTKDM4E
SCHEMBL3246488 0.80 MAPT (0.44) GALR2GALR1ALDH1A1MEN1KMT2A
SCHEMBL3240238 0.80 KDM4E (0.42) GALR2GALR1ALDH1A1MEN1KMT2A
SCHEMBL8097814 0.80 KDM4E (0.43) GALR2GALR1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936607-B2 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNOBECK A/S (DK) 2005-08-30 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNDBECK A/S (DK) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082587-A1 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety GALR3, GALR2, GALR1 GALR2 2/4885GALR1 3/4885ALDH1A1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.